A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients

Bibliography

• American Cancer Society. Cancer facts & figures 2015. American Cancer Society; Atlanta: 2015
   Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011;17(8):2081
   PubMed Web of Science ®Google Scholar
• Soda M, Takada S, Takeuchi K, et al. A mouse model for EML-4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008;105(50):19893
   PubMed Web of Science ®Google Scholar
• Ou S-H, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012;17(11):1351-75
   PubMed Web of Science ®Google Scholar
• Morales La Madrid A, Campbell N, Smith S, et al. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma. Target Oncol 2012;7(3):199-210
   PubMed Web of Science ®Google Scholar
• Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6(12 Pt 1):3314
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib vs chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368(25):2385
   PubMed Web of Science ®Google Scholar
• Mok T, Kim DW, Wu YL, et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 2014;32(5 Suppl):abstract 8002
   Google Scholar
• Li C, Alvey C, Bello A, et al. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol 2011;29(Suppl):abstract e13065
   Google Scholar
• Prescribing information. Xalkori (crizotinib) or capsules. Pfizer labs; New York, NY: August 2011
   Google Scholar
• Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443-5
   PubMed Web of Science ®Google Scholar
• West AH, Yamada SD, Salgia R, et al. Unique metastases of ALK mutated lun cancer activated to the adnexa of the uterus. Case Rep Clin Pathol 2014;1(2):151-4
   PubMedGoogle Scholar
• Camridge D, Bang YJ, Salgia R, et al. Activity and safety of crizotinib in patients with ALK-positive non-small cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13(10):1011-19
   PubMed Web of Science ®Google Scholar
• Ou SHI, Salgia R, Clark J. Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. J Thorac Oncol 2010;5(Suppl 5):S382
   Google Scholar
• O’bryant CL, Wenger SD, Kim M, Thompson LA. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother 2013;47(2):189-97
   PubMed Web of Science ®Google Scholar
• Palmer RH, Vernersson E, Grabbe C, et al. Anaplastic lymphoma kinase: signaling in development and disease. Biochem J 2009;420:345-61
   PubMed Web of Science ®Google Scholar
• Liu CN, Mathialagan N, Lappin P, et al. Crizotinib reduces the rate of dark adaption in the rat retina independent of ALK inhibition. Toxicol Sci 2015;143(1):116-25
   PubMed Web of Science ®Google Scholar
• Atkinson B, Barnett C, Choi S. Adult antiemetic management of chemotherapy-induced nausea and vomiting. The University of Texas M.D. Anderson Cancer Center, Houston, TX; 2013. Available from: http://www.mdanderson.org/education-and-research/resources-for-professionals/clinical-tools-and-resources/practice-algorithms/clin-management-cinv-adult-web-algorithm.pdf [Last accessed 24 November 2014]
   Google Scholar
• Doherty K, Wappel R, Talbert D, et al. Multi-parameter in vitro toxcitiy testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol 2013;272(1):245-55
   PubMed Web of Science ®Google Scholar
• Sahu A, Prabhash K, Noronha V, et al. Crizotinib: a comprehensive review. South Asian J Cancer 2013;2(2):91-7
   PubMedGoogle Scholar
• Ou SH, Azada M, Dy J, Stiber J. Asymptomatic profound sinus bradycardia (Heart rate <45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol 2011;6:2135-7
   PubMed Web of Science ®Google Scholar
• Nickens D, Tan W, Wilmer K, et al. A pharmacokinetics/pharmacodynamics evaluation of the concentration-QTc relationship of PF-02341066 (PF-1066), an ALK and c-MET/HGFR dual inhibitor administered to patients with advanced cancer [abstract #1673]. Poster presented at 101st annual meeting of the American Association for Cancer Research; 17 – 21 April 2010; Washington DC, USA
   Google Scholar
• Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase 1 study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(Suppl):abstract 2501
   Google Scholar
• Tabernero J, Elez M, Herranz M, et al. A pharmacodynamics/pharmacokinetic study of Ficlatuzumab in patients with advanced solid tumors and liver metastases. Clin Cancer Res 2014;20:2793-804
   PubMed Web of Science ®Google Scholar
• Weickhardt A, Rothman M, Salian-Mehta S, et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 2012;118(21):5302-9
   PubMed Web of Science ®Google Scholar
• Sargis RM, Salgia R. Multiple endocrine disruption by the MET/ALK inhibitor crizotinib in patients with non-small cell lung cancer. Am J Clinic Oncol 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Del Bravo J, Catizone A, Ricci G, et al. Hepatocyte growth factor-modulated rat Leydig cell functions. J Androl 2007;28:866-74
   Google Scholar
• Vernersson E, Khoo NK, Henriksson ML, et al. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr Patterns 2006;6:448-61
   PubMed Web of Science ®Google Scholar
• Yan L, Zhu TB, Wang LS, et al. Inhibitor effect of hepatocyte growth factor on cardiomyocytes apoptosis is partly related to reduced calcium sensing receptor expression during a model of simulated ischemia/reperfusion. Mol Biol Rep 2011;38:2695-701
   PubMed Web of Science ®Google Scholar
• Tachihara M, Kobayashi K, Ishikawa Y. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease. Jpn J Clin Oncol 2014;44:762-4
   PubMed Web of Science ®Google Scholar
• Yanagisawa S, Inoue A, Koarai A, et al. Successful crizotinib retreatment after crizotinib-induced interstitial lung disease. J Thorac Oncol 2013;8:e73-4
   PubMedGoogle Scholar
• Oser M, Janne P. A severe photosensitivity dermatitis caused by crizotinib. J Thorac Oncol 2014;9(7):e51
   Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in acquired patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82
   PubMed Web of Science ®Google Scholar
• Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor LDK378 currently in phase 1 and 2 clinical trials. J Med Chem 2013;56:5675-90
   PubMed Web of Science ®Google Scholar
• Li N, Michellys PY, Kim S, et al. Activity of a potent and selective phase 1 ALK inhibitor LDK378 in naïve and crizotinib-resistance preclinical tumor models. Presented at the AACR-NCI-EORC International Conference: Molecular Targets and Cancer Therapeutics; 12 – 16 November 2011; San Francisco
   Google Scholar
• Shaw A, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Gandhi L, Riely G, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small cell lung cancer (AF-002JG): results from the dose-finding portion of a phase ½ study. Lancet Oncol 2014;15(10):1119-28
   PubMed Web of Science ®Google Scholar
• ALK-associated non-small cell lung cancer clinical trials. My Cancer Genome: Genetically Informed Cancer Medicine. Vanderbilt-Ingram Program, Nashville, TN; Available from: http://www.mycancergenome.org/content/disease/lung-cancer/alk/66/ [Last accessed 24 November 2014]
   Google Scholar
• Mesaros EF, Ott GR, Dorsey BD. Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review. Expert Opin Ther Pat 2014;24(4):417-42
   PubMed Web of Science ®Google Scholar
• Crino L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011;29(Suppl):abstract 7514
   Google Scholar